Core Viewpoint - The article discusses the rising incidence and prevalence of Type 1 Diabetes (T1D) globally, emphasizing the need for innovative treatments beyond insulin replacement therapy, including immune modulation and gut microbiome interventions [2][5]. Group 1: Research Findings - A recent study published in Cell Reports Medicine indicates that restoring intestinal secondary bile acid synthesis through gut microbiota transplantation may improve pancreatic β cell function in T1D patients [3]. - The research highlights that T1D patients exhibit reduced gut microbiome diversity and an imbalance between harmful and beneficial bacteria, which correlates with impaired secondary bile acid metabolism [6][7]. - The study confirms that interventions targeting gut microbiota and their metabolites are safe and can enhance blood glucose control, reduce daily insulin dosage, and alleviate inflammation [6][9]. Group 2: Implications for Treatment - The findings suggest that targeting gut microbiota and secondary bile acid metabolism could be a promising approach for treating T1D, potentially leading to improved β cell function and metabolic health [9]. - The study also indicates that secondary bile acids are linked to β cell function in T1D patients, and gut microbiome markers may have diagnostic potential for the disease [7].

【SynBioCon】 获 悉， 2025年4月22日，教育部发布2024年度普通高等学校本科专业备案和审 批结果及《普通高等学校本科专业目录（2025年）》的通知。 5家高校获批设立合成生物学专业 ， 分别是陕西省—— 长治学院 ，江苏省—— 淮阴师范学院 ，湖北省—— 武 汉轻工大学 ，湖南省 —— 湖 南文理学院 ，广东省—— 深 圳理工大学 。 截止目前，国内已经有 11家高校开设合成生物学本科专业 ，之前的6家分别是： 2020年度—— 天津大学 2021年度—— 山西大学 2022年度—— 南京师范大学，青岛科技大学 2023年度—— 江南大学，湖北大学 本年度获批高校有什么特点和办学优势呢？ 01 长治学院 长治学院在2024年软科排名中 位列第440位。校友会2025长治学院专业排名中，该校的 生物科学 被评选为 中国顶尖应用型专业，全国排名第9， 化学生物学 为中国区域一流应用型专业。 02 淮阴师范学院 "材料与化工"为淮阴师范学院重点学科， 该校拥有 江苏省生物质能与酶技术重点实验室，在能源材料，绿 色合成，生物质化学等方面都有涉及。 软科2024中国大学排行榜中，淮阴师范学院全国排名为 ...

Group 1 - Baoli Pharma (Nanjing) Co., Ltd. has successfully obtained a patent for "a preparation and purification device, method, and application of ursodeoxycholic acid," showcasing its strong R&D capabilities and providing new opportunities for the pharmaceutical industry [1] - Ursodeoxycholic acid plays a crucial role in the treatment of various liver and gallbladder diseases, helping to dissolve cholesterol stones and alleviate patient pain [3] - The patented technology significantly enhances the purity and quality stability of ursodeoxycholic acid, offering more reliable and effective treatment options for patients [4] Group 2 - Baoli Pharma has previously achieved success in patenting vitamin B6 injection solutions, marking the latest patent in its innovation journey as a significant milestone [4] - The company emphasizes its commitment to R&D innovation and continuous investment, reflecting its strong technical foundation and innovative capabilities [4] - Baoli Pharma aims to integrate global pharmaceutical technology to safeguard human health, focusing on developing safe and high-quality products and services for the healthcare sector [4]

Core Viewpoint - Chuaning Bio reported a positive overall business performance for the fiscal year 2024, with significant growth in revenue and net profit, driven by increased sales and improved production efficiency [1][2] Financial Performance - The company achieved an operating income of 5.758 billion yuan, representing a year-on-year increase of 19.38% [1] - Net profit attributable to shareholders reached 1.4 billion yuan, up 48.88% year-on-year [1] - Basic earnings per share were 0.63 yuan, reflecting a growth of 50.00% compared to the previous year [1] Business Segments - The main business revenue breakdown includes: - Erythromycin thiocyanate: 32.35% - Cephalosporin intermediates: 24.96% - Penicillin intermediates: 41.95% - Other products: 0.74% [1] Strategic Development - The company adheres to a "dual-drive" strategy focusing on "biological fermentation" and "synthetic biology" [1][2] - Chuaning Bio has become a leading enterprise in the global biological fermentation technology industry, maintaining stable growth in product orders and prices [2] Investment and Innovation - The company invested 60 million yuan in a private equity fund to enhance its competitive edge and resource allocation [2] - A strategic partnership with Shanghai Jinchang Technology was established to integrate AI into fermentation and synthetic biology research, aiming to improve production efficiency and reduce costs [3] Future Outlook - Chuaning Bio plans to continue its "dual-drive" strategy, leveraging AI technology to maintain its leading position in the biological fermentation sector [4] - The company announced a profit distribution plan, proposing a cash dividend of 2.70 yuan per 10 shares, with total dividends since listing amounting to 1.3 billion yuan [4]